James Richard Porter Sells 27,000 Shares of Nuvalent, Inc. (NASDAQ:NUVL) Stock

Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) CEO James Richard Porter sold 27,000 shares of Nuvalent stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $78.46, for a total transaction of $2,118,420.00. Following the transaction, the chief executive officer now directly owns 249,062 shares of the company's stock, valued at $19,541,404.52. This represents a 9.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

James Richard Porter also recently made the following trade(s):

• On Wednesday, January 15th, James Richard Porter sold 27,000 shares of Nuvalent stock. The shares were sold at an average price of $75.99, for a total transaction of $2,051,730.00.
• On Monday, January 6th, James Richard Porter sold 17,301 shares of Nuvalent stock. The shares were sold at an average price of $79.68, for a total transaction of $1,378,543.68.
• On Monday, December 16th, James Richard Porter sold 27,000 shares of Nuvalent stock. The shares were sold at an average price of $86.61, for a total transaction of $2,338,470.00.

Nuvalent Stock Up 2.7 %

Nuvalent stock traded up $2.13 during midday trading on Thursday, hitting $82.39. 327,101 shares of the stock were exchanged, compared to its average volume of 475,365. The company has a fifty day simple moving average of $81.55 and a two-hundred day simple moving average of $88.05. Nuvalent, Inc. has a 52 week low of $61.79 and a 52 week high of $113.51. The stock has a market capitalization of $5.85 billion, a PE ratio of -23.74 and a beta of 1.38.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of NUVL. Creative Planning bought a new position in Nuvalent during the 3rd quarter worth approximately $232,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Nuvalent by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,147 shares of the company's stock worth $213,000 after acquiring an additional 382 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Nuvalent by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,417 shares of the company's stock worth $1,168,000 after acquiring an additional 4,472 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in Nuvalent by 29.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 21,516 shares of the company's stock worth $2,201,000 after acquiring an additional 4,957 shares during the last quarter. Finally, AlphaCentric Advisors LLC bought a new position in Nuvalent during the 3rd quarter worth approximately $716,000. Institutional investors own 97.26% of the company's stock.

Analyst Ratings Changes

NUVL has been the subject of several research reports. Wedbush restated an "outperform" rating and issued a $115.00 price objective on shares of Nuvalent in a research report on Monday, January 13th. UBS Group initiated coverage on shares of Nuvalent in a research report on Thursday, October 24th. They issued a "neutral" rating and a $100.00 price objective for the company. BMO Capital Markets raised their price objective on shares of Nuvalent from $132.00 to $134.00 and gave the company an "outperform" rating in a research report on Wednesday, November 13th. Finally, HC Wainwright reiterated a "buy" rating and set a $110.00 price target on shares of Nuvalent in a research report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Nuvalent has an average rating of "Moderate Buy" and an average target price of $112.36.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.